InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedica
15 February 2022 - 11:30PM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM), a leader in the research, development,
manufacturing and commercialization of rare cannabinoids, is
pleased to announce the appointment of Gerard (Jerry) P. Griffin
III as Vice President of Sales and Marketing at BayMedica, a wholly
owned subsidiary of InMed. Mr. Griffin will oversee the
commercialization of BayMedica’s health and wellness business
including the existing products and the launch of new rare
cannabinoid products.
Mr. Griffin has a wealth of experience across
various markets and with numerous cannabinoid products, and a
proven track record as a seasoned sales executive. He has held
several senior positions at both privately and publicly held
companies including Fortune 500 companies. Most recently, Mr.
Griffin was the Vice President of Sales and Business Development at
Creo Ingredients, a biotechnology-based ingredient company that
produces rare cannabinoids. Prior to Creo, he was the President of
a successful wellness company, overseeing all aspects of a business
that develops and distributes cannabinoid-based products. With his
extensive hands-on experience in the rapidly expanding cannabinoid
industry, he brings significant real-world knowledge across the
entire value chain to the Company.
“We are very excited to welcome Jerry to the
InMed / BayMedica family. Jerry is joining the team as a strong
strategic leader and has the requisite experience to oversee the
commercial ramp-up of B2B sales of rare cannabinoids products to
the consumer health and wellness market,” stated Shane Johnson, SVP
and General Manager of BayMedica. “Jerry is joining the team at a
very exciting inflection point as we anticipate the launch of
several new high-demand rare cannabinoids over the coming months.
This appointment reinforces our commitment to accelerate commercial
activities and grow market share in this burgeoning new segment of
the industry.”
About InMed: InMed
Pharmaceuticals is a global leader in the research, development,
manufacturing and commercialization of rare cannabinoids. Together
with its subsidiary BayMedica LLC, the Company has unparalleled
cannabinoid manufacturing capabilities to serve a spectrum of
consumer markets, including pharmaceutical and health and wellness.
InMed is also a clinical-stage company developing a pipeline of
rare cannabinoid therapeutics and dedicated to delivering new
treatment alternatives to patients that may benefit from
cannabinoid-based pharmaceutical drugs. For more information,
visit www.inmedpharma.com and www.baymedica.com.
Investor Contact: Colin ClancySenior Director,
Investor RelationsT: +1.604.416.0999E: cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: launching new rare cannabinoid products,
accelerating commercial activities and growing market share; the
commercial ramp-up of B2B sales of rare cannabinoids products to
the consumer health and wellness market; having unparalleled
cannabinoid manufacturing capabilities to serve a spectrum of
consumer markets, including pharmaceutical and health and wellness;
and, developing a pipeline of rare cannabinoid therapeutics and
dedicated to delivering new treatment alternatives to patients that
may benefit from cannabinoid-based pharmaceutical drugs.
With respect to the forward-looking information
contained in this news release, InMed has made numerous
assumptions. While InMed considers these assumptions to be
reasonable, these assumptions are inherently subject to significant
business, economic, competitive, market and social uncertainties
and contingencies.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein. A complete discussion
of the risks and uncertainties facing InMed’s stand-alone business
is disclosed in InMed’s Annual Report on Form 10-K and other
filings with the Security and Exchange Commission on
www.sec.gov.
All forward-looking information herein is
qualified in its entirety by this cautionary statement, and InMed
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Apr 2024 to May 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From May 2023 to May 2024